Clinical use of bisphosphonates

Current Opinion in Rheumatology

Volumn 8, Issue 4, 1996, Pages 384-391

  Devogelaer, Jean Pierre ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ETIDRONIC ACID; TILUDRONIC ACID;

BONE DISEASE; BONE REMODELING; DRUG USE; HUMAN; HYPERCALCEMIA; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0029781090     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199607000-00018     Document Type: Review

References (60)

1. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, Zhang D, Barbier A, Suda T: A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995, 17:137-144.
2. Azuma Y, Sato H, Oue Y, Okabe K, Ohta T, Tsuchimoto M, Kiyoki M: Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption In vitro and In experimental hypercalcemia models. Bone 1995, 16:235-245.
3. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF: Bisphosphonates promote apoptosis In murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995, 10:1478-1487.
4. Singer FR, Minoofar PN: Bisphosphonates in the treatment of disor• ders of mineral metabolism. Adv Endocrinol Metab 1995, 6:259-288. A practical review of the clinical use of bisphosphonates in various conditions.
5. Patel S, Coupland CAC, Stone MD, Hosking DJ: Comparison of methods of assessing response of Paget's disease to bisphosphonate therapy. Bone 1995, 16:193-197.
6. Yates AJP, Gray RES, Urwin GH, Preston CJ, Russell RGG, Percival RC, Atkins RM, Hamdy NAT, Beneton MNC, Kanis JA: Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet 1985, i:1474-1477.
7. Devogelaer J-P, Triki R, Nagan de Deuxchaisnes C: Apparent versus true acquired resistance to pamidronate in Paget's disease of bone. Bone Miner 1992, 17(suppl 1):67.
8. O'Doherty DP, McCloskey EV, Vasikaran S, Khan S, Kanis JA: The effects of intravenous alendronate in Pagef s disease of bone. J Bone Miner Res 1995, 10:1094-1100.
9. Nagant de Deuxchaisnes C: Paget's disease of bone: medical management In Endocrinology. Edited by DeGroot LJ. Philadelphia: W.B. Saunders; 1989:1211-1244.
10. Schweitzer DH, Oostendorp-Van De Ruit M, Van Der Pluijm G, Löwik CWGM, Papapoulos SE: Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dlmethylamlnohydroxypropylidene bisphosphonate. J Bone Miner Res 1995, 10:956-962.
11. McClung MR, Tou CKP, Goldstein NH, Picot C: Tiludronate therapy for Paget's disease of bone. Bone 1995, 17(suppl):493-496. A double-blind study of placebo versus two different doses of tiludronate. This study demonstrates that 400 mg of oral tiludronate administered daily for 3 months is a valuable therapy for active Paget's disease, as defined by biochemical indices of bone turnover.
12. Roux C, Gennari C, Farrerons J, Devogelaer JP, Mulder H, Kruse HP, Picot • C, Titeux L, Reginster JY, Dougados M: Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum 1995, 38:851-858. A double-blind, multicenter comparative study of tiludronate, 400 mg, administered orally daily for 6 months or 3 months followed by 3 months of placebo and oral etidronate 400 mg/d for 6 months. This study demonstrates a greater effectiveness of tiludronate given for 3 to 6 months than etidronate on the biologic parameters of Paget's disease. No clinical assessment, however, has been performed.
13. Devogelaer J-P, Stasse P, Malghem J, Maldague B, Nagant de Deuxchaisnes C: Comparative biological and radiological responses to oral etidronate and tiludronate in Paget's disease of bone. Bone Miner 1994, 25(suppl 1):82.
14. Wallace E, Wong J, Reid IR: Pamidronate treatment of the neurologic sequelae of pagetic spinal stenosis. Arch Intern Med 1995, 155:1813-1815.
15. Robertson AG, Reed NS, Ralston SH: Effect of oral clodronate on metastatic bone pain: a double-blind placebo-controlled study. J Clin Oncol 1995, 13:2427-2430.
16. O'Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA: Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. J Clin Oncol 1995, 13:929-934.
17. Adam Z, Prokes B, Hajek D, Vorlicek J: Increasing bone density in myeloma patients after the administration of clodronate. Acta Med Austriaca 1995, 22:9-12.
18. Body JJ, Dumon JC, Piccart M, Ford J: Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study. J Bone Miner Res 1995, 10:1191-1196.
19. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE: A randomised double-blind comparison of Intravenous pamidronate and clodronate in the hypercalcaemla of malignancy. Br J Cancer 1995, 72:1289-1293.
20. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC III, Yanover MJ, et al.: Intermittent cyclical etidronate treatment of postmenopausal osteoporosls. N Engl J Med 1990, 323:73-79.
21. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnut CH III: Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993, 95:557-567.
22. Marcus R: Cyclic etidronate: has the rose lost its bloom? Am J Med 1993, 95:555-556.
23. Wimalawansa SJ: Combined therapy with estrogen and etldronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 1995, 99:36-42. A randomized study of the use of cyclical etidronate administered alone or in combination with percutaneous estradiol showing a synergistic effect of etidronate and estradiol combined therapy at the lumbar spine (predominantly composed of trabecular bone) but not at the femoral neck (predominantly cortical bone). More importantly, osteomalacia was observed in 33% of cases treated for 4 years with etidronate alone, suggesting that the high bone turnover observed in early postmenopausal women could favor the adverse action of etidronate on bone mineralization.
24. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD: Different • effects of bisphosphonate and estrogen therapy on free and peptidebound cross-links excretion. J Bone Miner Res 1995, 10:641-649. A comparative study of the intensity of the response to therapy with bisphosphonate or estradiol measured in various assays of free and peptide-bound cross-links excretion. Bisphosphonate therapy markedly decreased cross-linked peptides without significant change in free cross-links excretion, contrasting with a decrease in both free and peptide-bound cross-links after estrogen therapy. These data suggest that these two antiresorptive therapies may affect the pattern of bone collagen degradation in different ways.
25. Struys A, Snelder AA, Mulder H: Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995, 99:235-242.
26. Valero MA, Loinaz C, Larrodera L, Leon M, Moreno E, Hawkins F: Calcitonin and bisphosphonates treatment in bone loss after liver transplantation. Calcif Tissue Int 1995, 57:15-19.
27. Lukert BP: Etidronate in the management of glucocorticoid-induced osteoporosis. Am J Med 1995, 99:233-234.
28. Filipponi P, Pedetti M, Fedeli L, Cini L, Palumbo R, Boldrini S, Massoni C, Cristallini S: Cyclical clodronate is effective in preventing post-menopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res 1995, 10:697-703.
29. Chesnut CH, III: Tiludronate: development as an osteoporosis therapy. Bone 1995, 17(suppl):517-519.
30. Neer RM: Skeletal safety of tiludronate. Bone 1995, 17(suppl):501-503.
31. Chappard D, Minaire P, Privat C, Berard E, Mendoza-Sarmiento J, Tournebise H, Basle MF, Audran M, Rebel A, Picot C, Gaud C: Effects of tiludronate on bone loss in paraplegic patients. J Bone Miner Res 1995, 10:112-118.
32. Valkema R, Vismans FJFE, Papapoulos SE, Pauwels EKJ, Bijvoet OLM: Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 1989, 5:183-192.
33. Devogelaer JP, Nagant de Deuxchaisnes C: Treatment of involutional osteoporosis with the bisphosphonate APD (dlsodium pamidronate): non-linear increase of lumbar bone mineral density. In Osteoporosis 1990. Edited by Christiansen C, Overgaard K. Aalborg: Handelstrykkeriet Aalborg ApS; 1990:1507-1509.
34. Devogelaer JP, Boutsen Y, Nagant de Deuxchaisnes C: A randomized controlled trial of APD (disodium pamidronate) given intravenously with and without sodium fluoride in involutional osteoporosis. In Osteoporosis 1990. Edited by Christiansen C, Overgaard K. Aalborg: Handelstrykkeriet Aalborg ApS; 1990:1504-1506.
35. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R: Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993, 14:690-709.
36. Landman JO, Papapoulos SE: Uninterrupted oral bisphosphonate (pamidronate) therapy of patients with osteoporosis is not associated with chronic stimulation of parathyroid hormone secretion. Osteoporosis Int 1995, 5:93-96.
37. Landman JO, Schweitzer DH, Frölich M, Hamdy NAT, Papapoulos SE: Recovery of serum calcium concentrations following acute hypocalcemia in patients with osteoporosis on long-term oral therapy with the bisphosphonate pamidronate. J Clin Endocrinol Metab 1995, 80:524-528.
38. Reeve J, Davies UM, Hesp R, McNally E, Katz D: Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride. BMJ 1990, 301:314-318.
39. Slovik DM, Rosenthal DI, Doppelt SH, Potts JT, Daly MA, Campbell JA, Neer RM: Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res 1986, 1:377-381.
40. Delmas PD, Vergnaud D, Arlot ME, Pastoureau P, Meunier PJ, Nilssen • MHL: The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate: is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 1995, 16:603-610. In a model of old sheep, closely resembling the situation in elderly humans, the anabolic effect of parathyroid hormone on bone is not maintained when parathyroid hormone is coadministered with a bisphosphonate. These data suggest that the activation of bone resorption may be a prerequisite for the anabolic effect of parathyroid hormone and that a combined parathyroid hormone-bisphosphonate therapy is not a valid strategy for treating osteoporosis.
41. Cheng P-T, Chan C, Müller K: Cyclical treatment of osteopenic ovariectomlzed adult rats with PTH (1-34) and pamidronate. J Bone Miner Res 1995, 10:119-126.
42. Mashiba T, Tanizawa T, Takano Y, Takahashi HE, Mori S, Norimatsu H: A histomorphometric study on effects of single and concurrent intermittent administration of human PTH (1-34) and bisphosphonates cimadronate on tibial metaphysis in ovariectomized rats. Bone 1995, 17(suppl):273-278.
43. 2 in OVX rats. Bone 1995, 17(suppl):261-266.
44. 2 alone in the long-term treatment of ovariectomized-induced osteopenic rats. Bone 1995, 17(suppl):267-272.
45. 2 alone in the proximal tibial metaphysis of ovariectomized rats. Bone 1995, 17(suppl):285-289.
46. 2 alone are equally anabolic on tibial shaft of ovariectomized rats. Bone 1995, 17(suppl):291-296.
47. Liang HH, Ma YF, Jee WSS, Pan Z, Setterberg RB, McOsker JE, Li XJ: Risedronate plus prostaglandin E2 is superior to prostaglandin E2 alone in maintaining the added bone after withdrawal in a non-growing bone site in ovariectomized rats. Bone 1995, 17(suppl):335-339.
48. Devogelaer JP, Triki R, Depresseux G, Nagant de Deuxchaisnes C: Remnant effect of pamidronate on bone metabolism in osteoporosis. J Bone Miner Res 1994, 9(suppl 1):329.
49. Landman JO, Hamdy NAT, Pauwels EKJ, Papapoulos SE: Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. Bone 1995, 17:615.
50. Chesnut CH, III, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, • Singer FR, Stock JL, Yood RA, Delmas PD, et al.: Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995, 99:144-152. A dose-ranging study of alendronate in postmenopausal osteoporotic women according to a densitometric definition. This study shows a larger increase in hip BMD with a 10-mg dose of alendronate.
51. Vasikaran SD, Khan S, McCloskey EV, Kanis JA: Sustained response to intravenous alendronate in postmenopausal osteoporosis. Bone 1995, 17:517-520.
52. Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, Gandolini G, Gnessi L, Laurenzi M, Lombardi A, et a/.: Effects of oral alendronate and Intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995, 17:383-390.
53. Liberman UA, Weiss SR, Bröil J, Minne HW, Quan H, Bell NH, Rodriguez-•• Portales J, Downs RW, Dequeker J, Favus M, et al.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995, 333:1437-1443. A large multicenter trial of various doses of alendronate versus placebo in post-menopausal women with vertebral osteoporosis as defined by densitometric criteria. A decrease in the vertebral fracture risk was observed in the combined alendronate groups compared with placebo.
54. Kanis JA, Gertz BJ, Singer F, Ortolani S: Rationale for the use of alen• dronate in osteoporosis. Osteaporosis Int 1995, 5:1-13. An interesting and comprehensive review of the chemistry, structure, and mechanism of action of bisphosphonates, with a special form on the clinical use of alendronate.
55. Sambrook PN: The treatment of postmenopausal osteoporosis. N Engl J Med 1995, 333:1495-1496.
56. Ruml LA, Dubois SK, Roberts ML, Pak CYC: Prevention of hypercalciuria and stone-forming propensity during prolonged bedrest by alendronate. J Bone Miner Res 1995, 10:655-662.
57. Maccagno A, Di Giorgio E, Roldan EJA, Caballero LE, Lloret AP: Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis. Scand J Rheumatol 1994, 23:211-214.
58. Bijvoet OLM, Frijlink WB, Jie K, van der Linden H, Meijer CJLM, Mulder H, van Paassen HC, Reitsma PH, te Velde J, de Vries E, van der Wey JP: APD in Paget's disease of bone: role of the mononuclear phagocyte system? Arthritis Rheum 1980, 23:1193-1204.
59. Ralston SH, Hacking L, Willocks L, Bruce F, Pitkeathly DA: Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis 1989, 48:396-399.
60. Tan PLJ, Ames R, Yeoman S, Ibbertson HK, Caughey DE: Effects of aminobisphosphonate infusion on biochemical indices of bone metabolism in rheumatoid arthritis. Br J Rheumatol 1989, 28:325-328.